返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Orthopedics Signs Strategic Agreement with Wiltrom Medical

[2017-08-11] 

Shanghai, China - Shanghai MicroPort Orthopedics Co., Ltd. ("MicroPort® Orthopedics") signed a strategic agreement with Taiwan-based Wiltrom Medical Device Co., Ltd. ("Wiltrom Medical"), which provides MicroPort® Orthopedics with the exclusive marketing rights for Wiltrom Medical's products Bone Graft Substitute and Spinal Fixation System in the Chinese mainland.
 
The signing ceremony was held in the headquarters of MicroPort®. Dr. Huangqian Liang, General Manager of Wiltrom Medical, and Zixin Weng, President of MicroPort® Orthopedics China, signed the agreement on behalf of the two companies. Glendy Wang, Chief Operation Officer ("COO") of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), Dr. Chengyun Yue, First Vice President of MicroPort® Corporate Strategy and Planning, and other senior management attended the ceremony.
 
Wiltrom Medical is a spin-off of Industrial Technology Research Institute. It is dedicated in the research and production of a wide range of various high-end, implantable, Class II and III medical devices. The development of products is strongly focused on innovation and to create a highly competitive private brand on the market internationally. This partnership aims to introduce two of Wiltrom Medical's primary products into the Chinese mainland market: Bone Graft Substitute and Spinal Fixation System. Bone Graft Substitute is in-house developed by Wiltrom Medical and has obtained approval from US Food and Drug Administration. It features high porosity, interconnected pores, and excellent biocompatibility and osteoconductivity. Spinal Fixation System with its matching instruments is jointly developed by Wiltrom Medical and US clinicians. It has high recognition in the Taiwan market as it fits clinical needs and effectively improves the surgical success rate.
 
MicroPort® COO Glendy Wang said: "Wiltrom Medical is dedicated to innovative R&D strategies, which highly accords with the R&D philosophy of MicroPort®, and the two products contained in the strategic agreement also reflect such innovative philosophies. This partnership is expected to enhance the market competitiveness of MicroPort® Orthopedics' spine and trauma products, and we hope through deep collaboration, the two parties would leverage complementary strength and resources to jointly promote the development of orthopedic medical device industry."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MPSC Issues Positive Profit Alert for 2017 1H Net Profit Expected to Increase 261%
[Next]:MicroPort® Awarded "Pudong Model Enterprise with Well-known Brand in International Trade"